Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors

Maysa M. Abu-Khalaf, Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut.
Megan A. Baumgart, Department of Medical Oncology, University of Rochester, Rochester, New York.
Scott N. Gettinger, Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut.
Indukala Doddamane, Department of Diagnostic Imaging, Yale University School of Medicine, New Haven, Connecticut.
David P. Tuck, EMD Serono, Billerica, Massachusetts.
Shihe Hou, Celgene Corporation, Berkeley Heights, New Jersey.
Nianhang Chen, Celgene Corporation, Berkeley Heights, New Jersey.
Catherine Sullivan, Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut.
Kimberly Lezon-Geyda, Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut.
Daniel Zelterman, Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut.
Christos Hatzis, Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut.
Hari Deshpande, Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut.
Michael P. Digiovanna, Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut.
Masoud Azodi, Department of Gynecologic Oncology, Yale University School of Medicine, New Haven, Connecticut.
Peter E. Schwartz, Department of Gynecologic Oncology, Yale University School of Medicine, New Haven, Connecticut.
Lyndsay N. Harris, Department of Medical Oncology, Case Western University, Cleveland, Ohio.

Document Type

Article

Publication Title

Cancer

Abstract

BACKGROUND: The optimal weekly oral dose of sirolimus and intravenous nanoparticle albumin-bound paclitaxel (nab-paclitaxel) were evaluated. METHODS: A phase 1b study was performed to evaluate escalating doses of oral sirolimus (5-60 mg) on days 2, 9, and 16 with intravenous nab-paclitaxel (100 mg/m(2) ) on days 1, 8, and 15 in a 28-day cycle. A run-in treatment of nab-paclitaxel (day -14) and sirolimus (day -7) was administered for pharmacokinetic and pharmacodynamic assessments. Clinical trial endpoints included dose-limiting toxicities (DLTs), maximum tolerated doses, and response rates. Pharmacodynamics included immunohistochemistry for phosphatase and tensin homolog, mammalian target of rapamycin (mTOR), AKT, phosphorylated AKT, S6K1, and phosphorylated S6K1; exploratory gene expression analysis; and [(18) F]fludeoxyglucose (FDG) positron emission tomography. RESULTS: Twenty-three patients with advanced solid tumors were treated. Fifteen patients had prior taxane therapy. Twenty-two patients were evaluable for responses. One patient had a complete response, and 5 patients had a partial response (3 confirmed). DLTs were seen in 1 patient each at 10 (grade 3 dyspnea/hypoxia) and 40 mg (grade 4 leukopenia/neutropenia) and in 2 patients at 60 mg (grade 3 fatigue and grade 4 pericardial effusion). Patients with higher expression of posttreatment AKT and a greater decline in FDG activity were more likely to have a treatment response or stable disease. CONCLUSIONS: Sirolimus showed an acceptable safety profile at a weekly dose of 40 mg with weekly intravenous nab-paclitaxel at 100 mg/m(2) on days 1, 8, and 15 every 28 days. The posttreatment AKT score and changes in FDG activity may have roles as early predictors of responses to mTOR inhibitors.

First Page

1817

Last Page

26

DOI

10.1002/cncr.29254

Publication Date

6-1-2015

Identifier

25649370 (pubmed); 10.1002/cncr.29254 (doi)

This document is currently not available here.

Share

COinS